<div id=toc></div>

# Table of Contents

- [q-bio.BM](#q-bio.BM) [Total: 4]
- [cs.LG](#cs.LG) [Total: 2]


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [1] [AMix-1: A Pathway to Test-Time Scalable Protein Foundation Model](https://arxiv.org/abs/2507.08920)
*Changze Lv,Jiang Zhou,Siyu Long,Lihao Wang,Jiangtao Feng,Dongyu Xue,Yu Pei,Hao Wang,Zherui Zhang,Yuchen Cai,Zhiqiang Gao,Ziyuan Ma,Jiakai Hu,Chaochen Gao,Jingjing Gong,Yuxuan Song,Shuyi Zhang,Xiaoqing Zheng,Deyi Xiong,Lei Bai,Ya-Qin Zhang,Wei-Ying Ma,Bowen Zhou,Hao Zhou*

Main category: q-bio.BM

TL;DR: AMix-1 是一个基于贝叶斯流网络的蛋白质基础模型，通过系统的训练方法（包括预训练缩放法则、涌现能力分析、上下文学习机制和测试时缩放算法）实现强大的性能。该模型展示了1.7亿参数的规模化能力，并通过多种技术实现了蛋白质设计的统一框架。


<details>
  <summary>Details</summary>
Motivation: 研究目标是开发一种可扩展的蛋白质基础模型，以统一蛋白质设计框架，并通过实验验证其性能提升，例如设计出活性提高50倍的AmeR变体。

Method: 采用贝叶斯流网络作为基础，结合预训练缩放法则、涌现能力分析、上下文学习策略（基于多序列对齐MSA）和测试时缩放算法。

Result: 成功训练出1.7亿参数的模型，设计出的AmeR变体活性提高了50倍。测试时缩放算法进一步提升了性能，验证了模型的扩展潜力。

Conclusion: AMix-1为下一代‘实验室-循环’蛋白质设计奠定了基础，展现了其在蛋白质工程中的广泛应用前景。

Abstract: We introduce AMix-1, a powerful protein foundation model built on Bayesian
Flow Networks and empowered by a systematic training methodology, encompassing
pretraining scaling laws, emergent capability analysis, in-context learning
mechanism, and test-time scaling algorithm. To guarantee robust scalability, we
establish a predictive scaling law and reveal the progressive emergence of
structural understanding via loss perspective, culminating in a strong
1.7-billion model. Building on this foundation, we devise a multiple sequence
alignment (MSA)-based in-context learning strategy to unify protein design into
a general framework, where AMix-1 recognizes deep evolutionary signals among
MSAs and consistently generates structurally and functionally coherent
proteins. This framework enables the successful design of a dramatically
improved AmeR variant with an up to $50\times$ activity increase over its wild
type. Pushing the boundaries of protein engineering, we further empower AMix-1
with an evolutionary test-time scaling algorithm for in silico directed
evolution that delivers substantial, scalable performance gains as verification
budgets are intensified, laying the groundwork for next-generation
lab-in-the-loop protein design.

</details>


### [2] [Conformation-Aware Structure Prediction of Antigen-Recognizing Immune Proteins](https://arxiv.org/abs/2507.09054)
*Frédéric A. Dreyer,Jan Ludwiczak,Karolis Martinkus,Brennan Abanades,Robert G. Alberstein,Pan Kessel,Pranav Rao,Jae Hyeon Lee,Richard Bonneau,Andrew M. Watkins,Franziska Seeger*

Main category: q-bio.BM

TL;DR: Ibex是一个泛免疫球蛋白结构预测模型，能够高精度预测抗体、纳米抗体和T细胞受体的可变域结构。


<details>
  <summary>Details</summary>
Motivation: 旨在区分并结合绑定和非绑定状态的蛋白质构象，以提升结构预测的准确性，并为大分子设计和治疗开发提供支持。

Method: 通过训练标记的apo和holo结构对，显式区分绑定和非绑定状态，并结合高分辨率抗体结构数据集进行优化。

Result: Ibex在分布外性能上优于现有工具，同时计算需求显著降低。

Conclusion: Ibex为抗体和大分子设计提供了高效且准确的预测工具。

Abstract: We introduce Ibex, a pan-immunoglobulin structure prediction model that
achieves state-of-the-art accuracy in modeling the variable domains of
antibodies, nanobodies, and T-cell receptors. Unlike previous approaches, Ibex
explicitly distinguishes between bound and unbound protein conformations by
training on labeled apo and holo structural pairs, enabling accurate prediction
of both states at inference time. Using a comprehensive private dataset of
high-resolution antibody structures, we demonstrate superior
out-of-distribution performance compared to existing specialized and general
protein structure prediction tools. Ibex combines the accuracy of cutting-edge
models with significantly reduced computational requirements, providing a
robust foundation for accelerating large molecule design and therapeutic
development.

</details>


### [3] [Advancing Structure Prediction of Biomolecular Interaction via Contact-Guided Sampling with HelixFold-S1](https://arxiv.org/abs/2507.09251)
*Lihang Liu,Yang Liu,Xianbin Ye,Shanzhuo Zhang,Yuxin Li,Kunrui Zhu,Yang Xue,Xiaonan Zhang,Xiaomin Fang*

Main category: q-bio.BM

TL;DR: HelixFold-S1 是一种基于接触概率的采样策略，能够提高生物分子结构预测的准确性，优于传统随机采样方法。


<details>
  <summary>Details</summary>
Motivation: 生物分子结构预测在分子生物学中至关重要，但在缺乏共进化信号时，准确预测复合物结构仍具有挑战性。传统的广泛采样方法由于构象多样性有限，效果有限。

Method: HelixFold-S1 通过预测分子实体间的接触概率，优先采样可能的结合位点和模式，生成多样化的结构候选集，从而提高准确性。

Result: HelixFold-S1 在多种生物分子相互作用（如蛋白-抗体、蛋白-蛋白等）中表现优于基线采样策略，且接触概率能有效指示结构预测难度。

Conclusion: HelixFold-S1 展示了定向采样策略在复杂生物分子相互作用结构建模中的潜力。

Abstract: Biomolecular structure prediction is essential to molecular biology, yet
accurately predicting the structures of complexes remains challenging,
especially when co-evolutionary signals are absent. While recent methods have
improved prediction accuracy through extensive sampling, aimless sampling often
provides diminishing returns due to limited conformational diversity. Here, we
introduce HelixFold-S1, a contact-guided sampling strategy that improves
structural accuracy. Rather than relying on indiscriminate sampling,
HelixFold-S1 predicts contact probabilities between molecular entities and uses
these predictions to prioritize sampling of likely binding sites and modes.
This targeted approach generates a diverse set of structural candidates,
enhancing the likelihood of identifying accurate conformations. We demonstrate
that HelixFold-S1 consistently outperforms baseline sampling strategies across
a range of biomolecular interactions, including protein-antibody,
protein-protein, protein-ligand, protein-RNA, and protein-DNA interfaces.
Furthermore, the predicted contact probabilities serve as a reliable indicator
of structural difficulty, guiding the allocation of sampling resources. These
results highlight the potential of targeted sampling strategies to advance the
structural modeling of complex biomolecular interactions during inference.

</details>


### [4] [Leveraging Conformational Diversity for Enhanced Structure-Based Virtual Screening: Insights from Molecular Dynamics Simulations of HIV-1 Protease-Ligand Complexes](https://arxiv.org/abs/2507.09658)
*Pei-Kun Yang*

Main category: q-bio.BM

TL;DR: 研究探讨了蛋白质和配体的构象多样性对结合能计算的影响，发现结合多构象能提高虚拟筛选的可靠性。


<details>
  <summary>Details</summary>
Motivation: 传统刚性对接方法假设受体结构固定，忽视了蛋白质和配体的构象灵活性，影响了结合能计算的准确性。

Method: 通过分子动力学模拟生成蛋白质和配体的结构集合，并使用RMSD聚类减少冗余。计算结合能时考虑范德华和静电相互作用。

Result: 实验表明，天然蛋白质-配体对的结合能较优，而非天然配对的结合能较差；聚类调参可平衡计算成本和准确性。

Conclusion: 在虚拟筛选中纳入多构象可提高预测可靠性，有助于更有效的药物发现。

Abstract: Structure-based virtual screening aims to identify high-affinity ligands by
estimating binding free energies between proteins and small molecules. However,
the conformational flexibility of both proteins and ligands challenges
conventional rigid docking methods that assume a fixed receptor structure. In
this study, we examined the impact of conformational diversity on binding
energy calculations using 79 HIV-1 protease-ligand complexes. Molecular
dynamics simulations were employed to generate structural ensembles for both
proteins and ligands in aqueous environments. RMSD-based clustering was applied
to reduce redundancy while preserving structural diversity. Binding energies
were computed using van der Waals and electrostatic interactions. The results
demonstrated that native protein-ligand pairs consistently yielded favorable
binding energies, whereas non-native pairings often failed to reproduce
binding. Furthermore, clustering thresholds influenced the balance between
computational cost and interaction accuracy. These findings underscore the
importance of incorporating multiple protein and ligand conformations in SBVS
protocols to improve prediction reliability and support more effective drug
discovery strategies.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [5] [ToxBench: A Binding Affinity Prediction Benchmark with AB-FEP-Calculated Labels for Human Estrogen Receptor Alpha](https://arxiv.org/abs/2507.08966)
*Meng Liu,Karl Leswing,Simon K. S. Chu,Farhad Ramezanghorbani,Griffin Young,Gabriel Marques,Prerna Das,Anjali Panikar,Esther Jamir,Mohammed Sulaiman Shamsudeen,K. Shawn Watts,Ananya Sen,Hari Priya Devannagari,Edward B. Miller,Muyun Lihan,Howook Hwang,Janet Paulsen,Xin Yu,Kyle Gion,Timur Rvachov,Emine Kucukbenli,Saee Gopal Paliwal*

Main category: cs.LG

TL;DR: ToxBench是首个为机器学习开发设计的大规模AB-FEP数据集，专注于人类雌激素受体α（ERα），包含8,770个配体-受体复合物及其结合自由能数据。DualBind模型通过双损失框架显著提升了预测性能。


<details>
  <summary>Details</summary>
Motivation: 药物发现和毒性评估需要准确的蛋白质-配体结合亲和力预测。机器学习（ML）受限于数据稀缺，而物理方法（如AB-FEP）计算成本高，因此开发ToxBench以填补这一空白。

Method: 提出ToxBench数据集，包含ERα配体复合物的AB-FEP计算数据，并测试了包括DualBind（双损失框架）在内的多种ML方法。

Result: DualBind在ToxBench上表现优越，能以低成本接近AB-FEP的准确性（实验验证RMSE为1.75 kcal/mol）。

Conclusion: ToxBench和DualBind证明了ML在预测结合自由能方面的潜力，为药物发现提供了高效工具。

Abstract: Protein-ligand binding affinity prediction is essential for drug discovery
and toxicity assessment. While machine learning (ML) promises fast and accurate
predictions, its progress is constrained by the availability of reliable data.
In contrast, physics-based methods such as absolute binding free energy
perturbation (AB-FEP) deliver high accuracy but are computationally prohibitive
for high-throughput applications. To bridge this gap, we introduce ToxBench,
the first large-scale AB-FEP dataset designed for ML development and focused on
a single pharmaceutically critical target, Human Estrogen Receptor Alpha
(ER$\alpha$). ToxBench contains 8,770 ER$\alpha$-ligand complex structures with
binding free energies computed via AB-FEP with a subset validated against
experimental affinities at 1.75 kcal/mol RMSE, along with non-overlapping
ligand splits to assess model generalizability. Using ToxBench, we further
benchmark state-of-the-art ML methods, and notably, our proposed DualBind
model, which employs a dual-loss framework to effectively learn the binding
energy function. The benchmark results demonstrate the superior performance of
DualBind and the potential of ML to approximate AB-FEP at a fraction of the
computational cost.

</details>


### [6] [Conditional Chemical Language Models are Versatile Tools in Drug Discovery](https://arxiv.org/abs/2507.10273)
*Lu Zhu,Emmanuel Noutahi*

Main category: cs.LG

TL;DR: SAFE-T是一个基于生物背景的化学建模框架，通过片段分子序列的条件似然优化分子设计和评分，显著提升药物发现的效率与可解释性。


<details>
  <summary>Details</summary>
Motivation: 现有生成化学语言模型（CLMs）在药物发现中受限于奖励信号不可靠和输出不可解释的问题。SAFE-T旨在通过生物背景条件建模克服这些限制。

Method: SAFE-T通过条件似然建模片段分子序列，支持任务如虚拟筛选和药物-靶点预测，并通过采样实现目标导向的分子生成。

Result: 在多项基准测试中，SAFE-T表现优于或等同于现有方法，且计算速度更快，同时通过片段水平归因验证了其可解释性。

Conclusion: 条件生成CLMs（如SAFE-T）能够统一评分与生成，加速早期药物发现，同时保持高效和可解释性。

Abstract: Generative chemical language models (CLMs) have demonstrated strong
capabilities in molecular design, yet their impact in drug discovery remains
limited by the absence of reliable reward signals and the lack of
interpretability in their outputs. We present SAFE-T, a generalist chemical
modeling framework that conditions on biological context -- such as protein
targets or mechanisms of action -- to prioritize and design molecules without
relying on structural information or engineered scoring functions. SAFE-T
models the conditional likelihood of fragment-based molecular sequences given a
biological prompt, enabling principled scoring of molecules across tasks such
as virtual screening, drug-target interaction prediction, and activity cliff
detection. Moreover, it supports goal-directed generation by sampling from this
learned distribution, aligning molecular design with biological objectives. In
comprehensive zero-shot evaluations across predictive (LIT-PCBA, DAVIS, KIBA,
ACNet) and generative (DRUG, PMO) benchmarks, SAFE-T consistently achieves
performance comparable to or better than existing approaches while being
significantly faster. Fragment-level attribution further reveals that SAFE-T
captures known structure-activity relationships, supporting interpretable and
biologically grounded design. Together with its computational efficiency, these
results demonstrate that conditional generative CLMs can unify scoring and
generation to accelerate early-stage drug discovery.

</details>
